SynthesisAnnals of medicine2025
Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Synthesis in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Crossing the toxicity threshold: a repeated landmark analysis of early toxicities and treatment modification during first-line CDK4/6 inhibitor therapy.Cancer chemotherapy and pharmacology · 2026Article
- Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Mini reviews in medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough some studies have indicated that CDK4/6 inhibitors are beneficial for the progression-free survival (PFS) and overall survival (OS) in breast cancer, evidence regarding the assessment of clinical response remains insufficient. Therefore, this study aims not only to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy in HR(+)/HER2(-) metastatic breast cancer, but also to analyze the objective response rate (ORR) and clinical benefit rate (CBR), providing comprehensive clinical outcome insights. MATERIALS AND
methodsA literature search was performed in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov focusing on studies published before 2022. The meta-analysis followed PRISMA guidelines and used RevMan 5.3 to conduct the analysis.
resultsEleven clinical trials published between 2015 and 2022 were included in our meta-analysis, with a total of 5572 eligible patients. This meta-analysis found that HR(+)/HER2(-) metastatic breast cancer treated with CDK4/6 inhibitors plus endocrine therapy can significantly improve progression-free survival(PFS) (HR: 0.55;
conclusionThis meta-analysis highlights the improvement of PFS, OS, ORR, and CBR in HR(+)/HER2(-) metastatic breast cancer for CDK4/6 inhibitors, with manageable and reversible toxicities. Clinicians should be aware of hematological toxicities, liver function abnormalities, and venous thromboembolism when using CDK4/6 inhibitors. These findings make CDK4/6 inhibitors a pivotal treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.